Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Mesothelioma: early-phase trial registry
27 of 47 indexed Mesothelioma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #307 of 28,707 conditions by registered trial count.
47 US clinical trials · 27 currently recruiting · #307 of 28,707 conditions by registered trial count
Mesothelioma: 47 US clinical trials tracked, 27 recruiting.
Mesothelioma is the subject of 47 registered US clinical trials on ClinicalTrials.gov, 27 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 38 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 7 of these trials.
Enrollment posture brief
Registry condition mesothelioma
OPEN 27 | RECR 57% | LATE 0 | EARLY 38 | RANK #307 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Endometrial Cancer (57% recruiting · 188 trials)
Mesothelioma lists 27 open slots (57% of 47 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Mesothelioma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Mesothelioma is recruiting above its size-band peers.
27 of 47 indexed trials (57.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Mesothelioma trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 7 of 47 trials (14.9%). 32 distinct sponsors appear on at least one study for this condition label.
-
Typical Mesothelioma enrolment sits around 103 participants.
Median target enrolment is 103 among the 47 trials that report a genuine target (sentinel values excluded). 22 of those (46.8%) plan for fewer than 100 participants.
-
Mesothelioma research is mostly interventional.
41 interventional and 6 observational studies make up this index (87.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
47 total, page 1 of 1
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
National Cancer Institute (NCI)
NCT01950572
Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes
National Cancer Institute (NCI)
NCT03830229
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
National Cancer Institute (NCI)
NCT04431024
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Genmab
NCT05579366
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Mohamed Abdel-Rahman
NCT04792463
Stereotactic Magnetic Resonance Guided Radiation Therapy
Dana-Farber Cancer Institute
NCT04115254
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Bristol-Myers Squibb
NCT05245500
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Vivace Therapeutics
NCT04665206
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Cancer Institute (NCI)
NCT06503146
Rapid Autopsy and Procurement of Cancer Tissue
National Cancer Institute (NCI)
NCT01851395
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
NCT07277413
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology
NCT03556228
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Udai Kammula
NCT03935893
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
Dana-Farber Cancer Institute
NCT03683680
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
A2 Biotherapeutics
NCT04981119
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma
NCT05873686
MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
Brigham and Women's Hospital
NCT05730816
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
NCT06710756
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
BridGene Biosciences
NCT06452160
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Cancer Institute (NCI)
NCT06885697
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
A&G Pharmaceutical
NCT05627960
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Memorial Sloan Kettering Cancer Center
NCT06057935
A Study of VET3-TGI in Patients With Solid Tumors
KaliVir Immunotherapeutics
NCT06444815
Olaparib in Patients With HRD Malignant Mesothelioma
University of Chicago
NCT04515836
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
Baylor College of Medicine
NCT05932199
A Study of Sacituzumab Govitecan in People With Mesothelioma
Memorial Sloan Kettering Cancer Center
NCT06477419
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
University of Chicago
NCT07126509
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals
NCT04913337
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
Novartis Pharmaceuticals
NCT04857372
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis Pharmaceuticals
NCT05544929
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Memorial Sloan Kettering Cancer Center
NCT02414269
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT05238883
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center
NCT00715611
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
NCT03907852
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05571839
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03918252
A Study of SGN-MesoC2 in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06466187
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
NCT05451849
Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
National Cancer Institute (NCI)
NCT00004547
Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma
Eli Lilly and Company
NCT00061477
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
NCT03652077
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
NCT03207347
Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma
Columbia University
NCT00859469
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
Columbia University
NCT00629343
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
NCT00703638
Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)
University of Alabama at Birmingham
NCT01204203
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Nagla Abdel Karim
NCT03023319
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 25 |
| Phase 2 | 13 |
Top Sponsors
Named interventions
Most-linked intervention names on Mesothelioma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Mesothelioma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Mesothelioma page
47 registered trials, 27 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 27 Mesothelioma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Mesothelioma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Mesothelioma condition card totals 47 registered trials; most-linked intervention cyclophosphamide; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.